Compound ID | 1785
MET-X
Class: Beta-lactamase inhibitor
| Agent Type: | Direct acting; Antibiotic adjuvant; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Inhibits metallo-beta-lactamases which hydrolyse carbapenems |
| Target Pathogen: | Active against Escherichia coli and Klebsiella pneumoniae |
| Combined with other compounds: | |
| Description: | Producing metallo-β-lactamase is just one reason for resistance to carbapenems; these enzymes are still uncommon in most high-income countries;only for use in combination with a carbapenem |
| Institute where first reported: | Infex Therapeutics (formerly AMR Center), Medivir |
| Year first mentioned: | 2022 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.